<DOC>
	<DOCNO>NCT00302393</DOCNO>
	<brief_summary>There two specific aim study . The first document pharmacokinetics dopamine transporter ( DAT ) receptor occupancy repeat administration orally administer , therapeutic dos short immediate release-methylphenidate hydrochloride ( IR-MPH ) long-acting formulation MPH ( OROS-MPH ) use positron emission tomography ( PET ) scan C-11 altropane ligand . The investigator hypothesize central nervous system ( CNS ) DAT occupancy OROS-MPH IR-MPH sequence great IR-MPH OROS-MPH sequence 5 hour initial administration CNS DAT occupancy two formulation intermediate . The second aim study ass whether abuse liability potential delayed , repeated administration different formulation MPH moderate oral delivery system delivery system slow onset may safer one rapid early release .</brief_summary>
	<brief_title>Study Examining Repeat Dosing OROS® Methylphenidate ( CONCERTA® ) Immediate Release Methylphenidate Healthy Adults</brief_title>
	<detailed_description>ROS-MPH 's pharmacokinetic profile use increase delivery MPH day ( ascend pharmacokinetic curve ) . It design replace IR-MPH TID treatment . The main target MPH brain dopamine transporter ( DAT ) . We exquisitely sensitive methodology measure DAT occupancy use C-11 Altropane Positron Emission Tomography ( PET ) . The time course decay C-11 Altropane permit repeat imaging , thus allow documentation pharmacokinetics DAT receptor occupancy . We test combination initial administration delay ( repeat ) administration two formulation : IR-MPH IR-MPH ; IR-MPH OROS-MPH ; OROS-MPH IR-MPH ; OROS-MPH OROS-MPH .</detailed_description>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Signed write informed consent participate study 2 . Age : 18 55 3 . If female , nonpregnant , nonnursing , use adequate form birth control negative plasma pregnancy test 4 . Supine stand blood pressure within range 110/60 150/90 mmHg 5 . Heart rate , rest 5 minute , within range 4690 beats/min 6 . Subjects within 20 % ideal weight height 7 . Right hand 1 . Subjects mark anxiety , tension , agitation since drug may aggravate symptom 2 . Subjects know hypersensitivity methylphenidate component Concerta Ritalin 3 . Subjects glaucoma 4 . Subjects motor tic family history diagnosis Tourette 's syndrome 5 . Subjects treat monoamine oxidase inhibitor ( MAOIs ) within 14 day discontinuation treatment MAOIs 6 . Diagnosis psychotic disorder , bipolar disorder , severe depression , severe anxiety , autism . Subjects mild mood , oppositional , conduct , anxiety disorder may permit participate consider appropriate investigator . 7 . Scores Baseline Scales : Hamilton Depression Scale &gt; 17 ( possible 67 21item scale ) ( Hamilton 1960 ) Beck Depression Inventory &gt; 19 ( possible 63 21item scale ) ( Beck et al 1961 ) Hamilton Anxiety Scale &gt; 21 ( possible 56 14item scale ) ( Hamilton 1959 ) 8 . Diagnosis ADHD ( attention deficit hyperactivity disorder ) 9 . History head trauma loss consciousness , organic brain disorder , seizure , neurosurgical intervention 10 . Any clinically significant chronic medical condition , judgment investigator 11 . Mental impairment evidence intelligence quotient ( I.Q . ) &lt; 75 12 . Exposure dopamine receptor antagonist within previous three ( 3 ) month 13 . Exposure radiopharmaceutical within four ( 4 ) week prior PET scan 14 . Subjects receive psychotropic medication 15 . Any clinically significant abnormality screen laboratory test , vital sign , 12lead ECG ( electrocardiogram ) , outside normal limit 16 . Any woman childbearing potential seek become pregnant suspect may pregnant 17 . Subjects know recent history ( within past six [ 6 ] month ) illicit drug alcohol dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>healthy volunteer</keyword>
</DOC>